Table 5.
Practice of Oncologists Toward Chemotherapy Resistance
| Items | Strongly Disagree |
Disagree | Uncertain | Agree | Strongly Agree |
|---|---|---|---|---|---|
| 1. Chemotherapy protocols should be improved. | 1 (1.6) | 1 (1.6) | 11 (17.2) | 46 (71.9) | 5 (7.8) |
| 2. I have easy access to guidelines I need on managing chemotherapy resistance |
0 (0) | 8 (12.5) | 20 (31.3) | 36 (56.3) | 0 (0) |
| 3. I have easy access to the materials I need to give advice on prudent chemotherapy use and chemotherapy resistance |
0 (0) | 14 (21.9) | 24 (37.5) | 24 (37.5) | 2 (3.2) |
| 4. In the last 12 months, Ireceivedsufficient information about chemotherapy resistance | 3 (4.7) | 28 (43.8) | 20 (31.3) | 13 (20.3) | 0 (0) |
| 5. On the basis of information I receive, I change my practice on prescribing and/or administering of chemotherapy | 1 (1.6) | 10 (15.6) | 26 (40.6) | 25 (39.1) | 2 (3.2) |
| 6. My country has a national action plan on chemotherapy resistance | 2 (3.2) | 27 (42.2) | 22 (34.4) | 13 (20.3) | 0 (0) |
| 7. Chemotherapy resistance is very common in my practical settings | 0 (0) | 13 (20.3) | 30 (46.9) | 19 (29.7) | 2 (3.2) |
| 8. Iusually consult my colleagues about any case of chemotherapy resistance | 3 (4.7) | 6 (9.4) | 8 (12.5) | 45 (70.3) | 2 (3.2) |
| 9. When there is chemotherapy resistance, alternative treatments, which are equally effective to chemotherapy, should be used |
0 (0) | 3 (4.7) | 15 (23.4) | 39 (60.9) | 7 (10.9) |
| 10. The sharing of information with patients on how to self-monitor and self-manage during chemotherapy resistance could be improved. |
0 (0) | 5 (7.8) | 15 (23.4) | 39 (60.9) | 5 (7.8) |
| 11. I treat a patient with chemotherapy resistance similarly to those who do not have chemotherapy resistance |
4 (6.3) | 39 (60.9) | 14 (21.9) | 7 (10.9) | 0 (0) |
| 12. Incidence of chemotherapy resistance is more common in specific types of cancers than others. |
0 (0) | 9 (14.1) | 13 (20.3) | 39 (60.9) | 3 (4.7) |
| 13. Cross-resistance in chemotherapy can be detected and rectified in patients. | 3 (4.7) | 2 (3.2) | 41 (64.1) | 8 (12.5) | 0 (0) |
| 14. Chemotherapy should be stopped immediately when it shows no signs of efficacy. | 2 (3.2) | 6 (9.6) | 19 (29.7) | 33 (51.6) | 4 (26.4) |
| 15. Physicians, nurses, and healthcare personnel should be trained in detecting chemotherapy resistance. |
0 (0) | 4 (6.3) | 7 (10.9) | 40 (62.5) | 13 (20.3) |
| 16. Oncologists should clearly explain to their patients about the consequences of chemotherapy resistance |
1 (1.6) | 3 (4.7) | 2 (3.2) | 48 (75) | 10 (15.6) |
| 17. Therapeutic privilege among oncologists should be revised to allow more transparency. | 1 (1.6) | 2 (3.2) | 12 (18.8) | 38 (59.4) | 11 (17.2) |